B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination
Copyright © 2022. Published by Elsevier Inc..
B cells are important in immunity to both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and vaccination, but B cell receptor (BCR) repertoire development in these contexts has not been compared. We analyze serial samples from 171 SARS-CoV-2-infected individuals and 63 vaccine recipients and find the global BCR repertoire differs between them. Following infection, immunoglobulin (Ig)G1/3 and IgA1 BCRs increase, somatic hypermutation (SHM) decreases, and, in severe disease, IgM and IgA clones are expanded. In contrast, after vaccination, the proportion of IgD/M BCRs increase, SHM is unchanged, and expansion of IgG clones is prominent. VH1-24, which targets the N-terminal domain (NTD) and contributes to neutralization, is expanded post infection except in the most severe disease. Infection generates a broad distribution of SARS-CoV-2-specific clones predicted to target the spike protein, while a more focused response after vaccination mainly targets the spike's receptor-binding domain. Thus, the nature of SARS-CoV-2 exposure differentially affects BCR repertoire development, potentially informing vaccine strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Cell reports - 38(2022), 7 vom: 15. Feb., Seite 110393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kotagiri, Prasanti [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.02.2022 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2022.110393 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336759622 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336759622 | ||
| 003 | DE-627 | ||
| 005 | 20240425232110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2022.110393 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM336759622 | ||
| 035 | |a (NLM)35143756 | ||
| 035 | |a (PII)S2211-1247(22)00114-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kotagiri, Prasanti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.02.2022 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Inc. | ||
| 520 | |a B cells are important in immunity to both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and vaccination, but B cell receptor (BCR) repertoire development in these contexts has not been compared. We analyze serial samples from 171 SARS-CoV-2-infected individuals and 63 vaccine recipients and find the global BCR repertoire differs between them. Following infection, immunoglobulin (Ig)G1/3 and IgA1 BCRs increase, somatic hypermutation (SHM) decreases, and, in severe disease, IgM and IgA clones are expanded. In contrast, after vaccination, the proportion of IgD/M BCRs increase, SHM is unchanged, and expansion of IgG clones is prominent. VH1-24, which targets the N-terminal domain (NTD) and contributes to neutralization, is expanded post infection except in the most severe disease. Infection generates a broad distribution of SARS-CoV-2-specific clones predicted to target the spike protein, while a more focused response after vaccination mainly targets the spike's receptor-binding domain. Thus, the nature of SARS-CoV-2 exposure differentially affects BCR repertoire development, potentially informing vaccine strategies | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a B cell receptor repertoire | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 vaccination | |
| 650 | 7 | |a Immunoglobulin Heavy Chains |2 NLM | |
| 650 | 7 | |a Immunoglobulin Isotypes |2 NLM | |
| 650 | 7 | |a Immunoglobulin Variable Region |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, B-Cell |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Mescia, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Rae, William M |e verfasserin |4 aut | |
| 700 | 1 | |a Bergamaschi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Tuong, Zewen K |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Lorinda |e verfasserin |4 aut | |
| 700 | 1 | |a Hunter, Kelvin |e verfasserin |4 aut | |
| 700 | 1 | |a Gerber, Pehuén P |e verfasserin |4 aut | |
| 700 | 1 | |a Hosmillo, Myra |e verfasserin |4 aut | |
| 700 | 0 | |a Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration |e verfasserin |4 aut | |
| 700 | 1 | |a Hess, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Clatworthy, Menna R |e verfasserin |4 aut | |
| 700 | 1 | |a Goodfellow, Ian G |e verfasserin |4 aut | |
| 700 | 1 | |a Matheson, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a McKinney, Eoin F |e verfasserin |4 aut | |
| 700 | 1 | |a Wills, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ravindra K |e verfasserin |4 aut | |
| 700 | 1 | |a Bradley, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Bashford-Rogers, Rachael J M |e verfasserin |4 aut | |
| 700 | 1 | |a Lyons, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kenneth G C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 38(2022), 7 vom: 15. Feb., Seite 110393 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:7 |g day:15 |g month:02 |g pages:110393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2022.110393 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 7 |b 15 |c 02 |h 110393 | ||